CNBC's Dominic Chu reports activist investor Carl Icahn will now include Facebook as a forum to disclose information and communicate with investors.» Read More
In what may be a CNBC first, two adversaries in a hostile takeover attempt went head-to-head on live television!
HE is a billionaire several times over. He has spent the better part of four decades terrorizing corporate chiefs and battling entrenched boards. His name is emblazoned on a stadium on an island in the East River, a laboratory at Princeton, a science center at the Choate Rosemary Hall school in Connecticut and charter schools in the Bronx.
Lawyers for billionaires Donald Trump and Carl Icahn are in court playing a real-life version of Monopoly over who should control some prized Atlantic City property.
After Carl Icahn upped his stake in Lions Gate, market chatter exploded. What must you know about his LGF trade as well as his Amylin and Genzyme stakes?
Lions Gate stock got a boost on the news that Icahn is looking to grow his 18.9 percent control of the company to 29.9 percent, offering $6 per share for 13 million shares, though as of now it hasn't hit that $6 mark.
When it comes to the jobs report, good news is bad news and bad news is bad news, says Gary Kaminsky. What does he mean?
Carl Icahn and Take Two Interactive Software are hardly strangers. The investor raised eyebrows Thursday after reporting an 11.3 percent stake in the video game publisher. Given his activist shareholder history, some took that as a sign that Take Two would soon be back on the sales block.
Billionaire investor Carl C. Icahn said Friday he has agreed to buy a majority of the first-lien bank debt of Trump Entertainment Resorts, which owns three resorts in Atlantic City, N.J.
As you may know we spoke with Carl Icahn on the Halftime Report. Find out what he told us about Yahoo!
Fast Money friend Carl Icahn is shaking things up again this time with an unprecedented offer extended to CIT’s small bondholders. And he revealed his entire strategy to us!
Activist investor Carl Icahn is resigning from Yahoo's board of directors because he no longer has enough time to devote to the Internet company.
There is a real risk of a double-dip recession and the market is acting in a "schizophrenic" way, which could cause a "bloodbath" for investors, billionaire investor Carl Icahn told CNBC Friday.
Warren Buffett is one of twenty-seven business, government, and academic leaders endorsing what's described as a "bold call to end the focus on value-destroying short-termism" in financial markets. A new statement from the Aspen Institute argues that shareholders are playing a key role by pushing corporations for short-term stock price gains at the expense of long-term sustainability.
After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.
Initial bids for Qwest Communications' long-distance business are below the $2 billion to $3 billion the telecommunications company sought, The Wall Street Journal reported Thursday.
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.
Get ready folks: America is about to own a car company. As of Monday, we the taxpayers will own more than 70 percent of GM. Whether the company will be formally renamed Government Motors remains to be seen. But that’s what it will be.
It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.
Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.